Warning: The NCBI web site requires JavaScript to function. more...
Retailers' knowledge of tobacco harm reduction following the introduction of a new brand of smokeless tobacco.
Heavner KK, Rosenberg Z, Tenorio F, Phillips CV.
Harm Reduct J. 2010 Jul 29;7:18.
Related citations
Smokers' beliefs about the relative safety of other tobacco products: findings from the ITC collaboration.
O'Connor RJ, McNeill A, Borland R, Hammond D, King B, Boudreau C, Cummings KM.
Nicotine Tob Res. 2007 Oct;9(10):1033-42.
Will the next generation of "safer" cigarettes be safer?
Warner KE.
J Pediatr Hematol Oncol. 2005 Oct;27(10):543-50. Review.
European Union policy on smokeless tobacco: a statement in favour of evidence based regulation for public health.
Bates C, Fagerström K, Jarvis MJ, Kunze M, McNeill A, Ramström L.
Tob Control. 2003 Dec;12(4):360-7.
US smokers' reactions to a brief trial of oral nicotine products.
O'Connor RJ, Norton KJ, Bansal-Travers M, Mahoney MC, Cummings KM, Borland R.
Harm Reduct J. 2011 Jan 10;8(1):1.
Final Report on Carcinogens Background Document for Formaldehyde.
National Toxicology Program.
Rep Carcinog Backgr Doc. 2010 Jan;(10-5981):i-512.
Final Report on Carcinogens Background Document for Styrene.
Rep Carcinog Backgr Doc. 2008 Sep;(8-5978):i-398.
Effect of smokeless tobacco product marketing and use on population harm from tobacco use policy perspective for tobacco-risk reduction.
Kozlowski LT.
Am J Prev Med. 2007 Dec;33(6 Suppl):S379-86. Review.
Why California retailers stop selling tobacco products, and what their customers and employees think about it when they do: case studies.
McDaniel PA, Malone RE.
BMC Public Health. 2011 Nov 8;11:848.
Relative harm of snus and cigarettes: what do Norwegian adolescents say?
Øverland S, Hetland J, Aarø LE.
Tob Control. 2008 Dec;17(6):422-5. Epub 2008 Oct 10.
Snuffing out cigarette sales and the smoking deaths epidemic.
Laugesen M.
N Z Med J. 2007 Jun 15;120(1256):U2587. Review.
Retail promotions and perceptions of R.J. Reynolds' novel dissolvable tobacco in a US test market.
Romito LM, Saxton MK, Coan LL, Christen AG.
Harm Reduct J. 2011 May 15;8(1):10.
Should the health community promote smokeless tobacco (snus) as a harm reduction measure?
Gartner CE, Hall WD, Chapman S, Freeman B.
PLoS Med. 2007 Jul;4(7):e185.
Tobacco harm reduction: an alternative cessation strategy for inveterate smokers.
Rodu B, Godshall WT.
Harm Reduct J. 2006 Dec 21;3:37.
Assessment of Swedish snus for tobacco harm reduction: an epidemiological modelling study.
Gartner CE, Hall WD, Vos T, Bertram MY, Wallace AL, Lim SS.
Lancet. 2007 Jun 16;369(9578):2010-4.
Evaluating the acute effects of oral, non-combustible potential reduced exposure products marketed to smokers.
Cobb CO, Weaver MF, Eissenberg T.
Tob Control. 2010 Oct;19(5):367-73. Epub 2009 Apr 2.
Should Australia lift its ban on low nitrosamine smokeless tobacco products?
Gartner CE, Hall WD.
Med J Aust. 2008 Jan 7;188(1):44-6.
Pilot study on lower nitrosamine smokeless tobacco products compared with medicinal nicotine.
Mendoza-Baumgart MI, Tulunay OE, Hecht SS, Zhang Y, Murphy S, Le C, Jensen J, Hatsukami DK.
Nicotine Tob Res. 2007 Dec;9(12):1309-23.
Monitoring Tobacco-Specific N-Nitrosamines and Nicotine in Novel Marlboro and Camel Smokeless Tobacco Products: Findings From Round 1 of the New Product Watch.
Stepanov I, Biener L, Knezevich A, Nyman AL, Bliss R, Jensen J, Hecht SS, Hatsukami DK.
Nicotine Tob Res. 2011 Oct 29. [Epub ahead of print]
Smokeless tobacco use: harm reduction or induction approach?
Hatsukami DK, Lemmonds C, Tomar SL.
Prev Med. 2004 Mar;38(3):309-17. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on